Filter Results
:
(3,383)
Show Results For
-
All HBS Web
(3,383)
- People (9)
- News (692)
- Research (2,156)
- Events (33)
- Multimedia (26)
- Faculty Publications (1,256)
Show Results For
-
All HBS Web
(3,383)
- People (9)
- News (692)
- Research (2,156)
- Events (33)
- Multimedia (26)
- Faculty Publications (1,256)
- March 2016 (Revised March 2022)
- Teaching Note
Evive Health and Workplace Influenza Vaccinations
By: John Beshears
Evive Health is a company that manages communication campaigns on behalf of health insurance plans and large employers. Using big data techniques and insights from behavioral economics, Evive deploys targeted and effective messages that improve individuals' health...
View Details
Keywords:
Vaccination;
Influenza;
Flu Shot;
Preventive Care;
Health Care;
Behavioral Economics;
Choice Architecture;
Nudge;
Experimental Design;
Randomized Controlled Trial;
RCT;
Causal Inference;
Health Care and Treatment;
Insurance;
Health;
Consumer Behavior;
Health Testing and Trials;
Communication Strategy;
Insurance Industry;
Health Industry
- 2010
- Chapter
From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance
By: Arthur A. Daemmrich
Adverse drug reactions pose distinct but potentially catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Testing and Trials;
Business and Government Relations;
Risk and Uncertainty;
Safety;
Pharmaceutical Industry;
United States
Daemmrich, Arthur A. "From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance." Chap. 13 in The Fragmentation of U.S. Health Care: Causes and Solutions, edited by Einer Elhauge, 301–322. Oxford: Oxford University Press, 2010.
- January 2017
- Supplement
Terrapin Laboratory: Exercise
By: Joseph B. Fuller and Christopher Payton
In this exercise, we examine the capital requirements of Terrapin Laboratory as they contemplate entering into a new market segment. The company is faced with two potential financing options which have different effects on the ownership structure of the company....
View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Testing and Trials;
Health Care and Treatment;
Business Model;
Problems and Challenges;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- 07 Aug 2000
- Research & Ideas
Rocket Science Retailing
Retailers can significantly improve forecast accuracy simply by updating their predictions based on early sales data, tracking the accuracy of their forecasts, getting product testing right, and using a variety of forecasting approaches....
View Details
- 12 Dec 2022
- Research & Ideas
Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them
October. However, when the drug testing panel includes a proportionate share of Black participants, doctors are much more willing to write a prescription. Black patients, in turn, were more likely to trust a medicine when clinical trials...
View Details
- Profile
Mike Monagle
business and then moved into a strategic role managing company interests in Asia. As it became clearer that Mike wanted to build a business of his own, he recognized a need to expand his skills and “reflect on my future,” he says. “In the right program, I could View Details
- 16 May 2016
- HBS Case
Food Safety Economics: The Cost of a Sick Customer
when more than 50 people in 11 states were sickened by an initial E. coli outbreak. “Do those smaller local organic growers have the experience, resources, and commitment to test their products for various food safety risks?” The chain...
View Details
- 01 Jun 2004
- News
Who, Me?
online, specifically to Tickle.com, a social interaction Web site founded and run by James Currier (MBA ’99). “Tickle is an interpersonal media company about everyone’s favorite subject: themselves,” Currier explained to the New York Times (March 8, 2004). The company...
View Details
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company...
View Details
Keywords:
Cash Burn;
Cash Flow Analysis;
Pharmaceutical Companies;
Founder;
Artificial Intelligence;
AI;
Entrepreneurship;
Health Testing and Trials;
Health Care and Treatment;
Decision Making;
Market Entry and Exit;
AI and Machine Learning;
Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)
- February 2020
- Teaching Note
Theranos: Who Has Blood on Their Hands? (A) and (B)
By: Nien-he Hsieh and Christina R. Wing
Teaching Note for HBS Nos. 619-039 and 320-091.
View Details
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had...
View Details
Keywords:
Entrepreneurship;
Governing Rules, Regulations, and Reforms;
Health Testing and Trials;
Marketing Strategy;
Product Positioning;
Genetics;
Biotechnology Industry;
Europe;
United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- 15 Sep 2003
- Research & Ideas
The Lessons of New-Market Disruption
Teradyne: Testing Opportunity In 1994, Teradyne, a leading provider of machines that test the quality of microprocessors and other integrated circuits as they come off the assembly line, saw an opportunity...
View Details
- 23 Jul 2008
- Sharpening Your Skills
Sharpening Your Skills: Balanced Scorecard in Action
reduce the gap between strategy and execution? Does the BSC work in testing strategy? How Can The Balanced Scorecard Improve Corporate Governance? Working Paper: Improving Corporate Governance with the Balanced Scorecard The authors...
View Details
- Mar 2012
- Article
Rethinking School
Economists have found that the higher a country's academic test scores, the faster its GDP grows. That puts the United States' perennially mediocre test scores in a particularly ominous light. Progress is...
View Details
- 17 Feb 2016
- Research & Ideas
Man vs. Machine: Which Makes Better Hires?
Some companies have begun relying more on computer-administered tests than human interviewers to find the best applicants. New research by Harvard Business School Assistant Professor Danielle Li and colleagues suggests that in this case,...
View Details
- Profile
Lindsay Hyde
in a simulated climb of Mt. Everest,” she says. “It was a great way to start the year, to begin thinking about how we want to develop as leaders.” In FIELD 2, Lindsay and her team helped an Indian retailer, Nalli Silk Sarees, develop a new service for the home-goods...
View Details
- 01 Mar 2016
- News
Off Script
(Thinkstock) Prescription drug spending increased by more than 13 percent in the United States in 2014, raising health insurance premiums and the ire of consumers and politicians. The reasons behind the rise are many, including the high cost of drug development—as much...
View Details
- October 2020
- Teaching Plan
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,...
View Details
- 19 Aug 2016
- News
Lending a Hand to Small Businesses in Emerging Markets
In emerging markets, where traditional credit scores are rare, how can lenders decide who is creditworthy? Just ask, says DJ DiDonna (MBA 2010), cofounder and chief strategy officer of the for-profit Entrepreneurial Finance Lab. The company has developed a 20- to...
View Details